Novartis transferred the exclusive import, commercial promotion, and distribution rights in China for two ophthalmic drugs to Kangzhe Pharmaceutical.
November 2, 2025
Source: drugdu
95
On October 27, Jiemian News learned from Novartis that Novartis and Kangzhe Pharmaceutical's wholly-owned subsidiary, Kangzhe Weisheng, officially signed a strategic cooperation agreement. Effective November 1, 2025, Novartis will transfer the exclusive import, commercial promotion, and distribution rights in China for two of its ophthalmic products, NoxD (ranibizumab injection) and Beyotime (buxizumab injection), to Kangzhe Weisheng for a period of five years.
Novartis stated that this strategic agreement signifies a further step in implementing its global "focus" strategy, concentrating on four core therapeutic areas—cardiovascular, renal and metabolic, oncology, and immunology and neuroscience—to more efficiently integrate resources and provide patients with innovative medicines with high clinical value.thing.
https://finance.eastmoney.com/a/202510273545245535.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
